‘Like trying to hit a moving target’: Why it’s so difficult to attack cancer with targeted gene therapies

new drug combo could help immune cells target and destroy cancer cells

We are, it seems, still a long way off from a cure, in any ordinary sense of the term. Yet one important reason for this, which the [Pan-Cancer Analysis of Whole Genomes project] makes clear, is that treating cancer is, evolutionarily speaking, like trying to hit a moving target. Cancer doesn’t just appear randomly, and it certainly doesn’t grow as a unit of one type of cancer cell; like any organism, it evolves within the environment it perpetuates.

Take a hypothetical case where a tumor is made up of two types of cells (though, in reality, the number of types will be far greater). In the absence of treatment, the tumor’s cells will not only compete with those of the person in which they live, but with each other.

Yet what happens if a doctor attacks one of those cell types with a targeted therapy that relies on specific cell signatures to find its target? You probably guessed it—one of the competitor cell types dies, leaving the other type to grow without restriction.

Still, there is hope. Researchers across disciplines are starting to join together to combine artificial intelligence, mathematical modeling, medical oncology and evolutionary biology to anticipate how cancer will evolve.

Read the original post

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot-2026-06-17-at-12.31.01-PM
Viewpoint: The dangerous influence of ‘woke’ post-modernism in science
Screenshot-2026-06-26-at-10.14.50-AM
Viewpoint: The facts behind the grifter-promoting wellness and anti-aging peptide craze: Don’t waste your money
ChatGPT-Image-Jun-26-2026-01_21_33-PM
How the dubious, Trump-backed, addictive drug kratom could enrich cabinet secretary Markwayne Mullin
ChatGPT-Image-Jun-25-2026-12_23_17-PM
No, Bill Gates did not secretly engineer ticks to promote veganism
Screenshot-2026-06-25-at-11.18.03-AM
Viewpoint: Appreciating a simpler past without swallowing the misleading ‘nature is healthier and safer’ myth
ChatGPT-Image-Mar-10-2026-01_39_01-PM
Viewpoint—“Miracle molecule” debunked: Why acemannan supplements don’t work
ChatGPT-Image-Jun-26-2026-12_10_16-PM
Europe’s heat wave fueled recycled climate-denial narratives and harassment of climate scientists
ChatGPT-Image-Jun-19-2026-04_11_20-PM
Daubert for Dummies—Scientific Reliability in U.S. Courts: Daubert, Rule 702, and Made-for-Litigation Evidence
ChatGPT-Image-Jun-17-2026-10_52_43-AM
Anguished parents, doctors in tears: Utah’s long measles outbreak takes a toll
Screenshot-2026-06-25-at-1.48.40-PM
Glyphosate affirmed as safe: Supreme Court rejects lawsuit claiming Roundup herbicide causes cancer, upholding EPA determination
ChatGPT-Image-Jun-26-2026-11_34_33-AM
Viewpoint: RFK, Jr.’s vaccine subterfuge campaign now flies below the media radar
ChatGPT-Image-Jun-23-2026-01_12_57-PM
After Mel Gibson’s Joe Rogan comments, grifters promoting ivermectin, without evidence, as a hantavirus preventive 
ChatGPT-Image-Jun-23-2026-03_12_23-PM
Is cellular reprogramming junk science? Nearly 20 patients are getting eye injections in the first FDA-cleared cellular trial
Screenshot-2026-06-22-at-9.04.46-PM
Kennedy's nutrition prescription for medical schools: Real problem, bad cure
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.